Cargando…
A Phthalimide Derivative That Inhibits Centrosomal Clustering Is Effective on Multiple Myeloma
Despite the introduction of newly developed drugs such as lenalidomide and bortezomib, patients with multiple myeloma are still difficult to treat and have a poor prognosis. In order to find novel drugs that are effective for multiple myeloma, we tested the antitumor activity of 29 phthalimide deriv...
Autores principales: | Shiheido, Hirokazu, Terada, Fukiko, Tabata, Noriko, Hayakawa, Ichigo, Matsumura, Nobutaka, Takashima, Hideaki, Ogawa, Yoko, Du, Wenlin, Yamada, Taketo, Shoji, Mitsuru, Sugai, Takeshi, Doi, Nobuhide, Iijima, Shiro, Hattori, Yutaka, Yanagawa, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382596/ https://www.ncbi.nlm.nih.gov/pubmed/22761710 http://dx.doi.org/10.1371/journal.pone.0038878 |
Ejemplares similares
-
A Novel Phthalimide Derivative, TC11, Has Preclinical Effects on High-Risk Myeloma Cells and Osteoclasts
por: Matsushita, Maiko, et al.
Publicado: (2015) -
An Anilinoquinazoline Derivative Inhibits Tumor Growth through Interaction with hCAP-G2, a Subunit of Condensin II
por: Shiheido, Hirokazu, et al.
Publicado: (2012) -
mRNA Display Selection of an Optimized MDM2-Binding Peptide That Potently Inhibits MDM2-p53 Interaction
por: Shiheido, Hirokazu, et al.
Publicado: (2011) -
MIP-2A Is a Novel Target of an Anilinoquinazoline Derivative for Inhibition of Tumour Cell Proliferation
por: Tokunaga, Mayuko, et al.
Publicado: (2013) -
Structural Basis for Inhibition of the MDM2:p53 Interaction by an Optimized MDM2-Binding Peptide Selected with mRNA Display
por: Nagata, Takashi, et al.
Publicado: (2014)